There is consensus that we need to develop better understanding of disease biology and pathways to select better targets, better incorporation of translational approaches and better advancement of compelling opportunities that can transform patient lives. This session will hear panelists discuss the following:
• Discovering - What do we need to do better in further understanding neuroscience disease biology? What technology investments are needed to drive success? What types of collaborations/partnerships would make sense?
•Translational - What are the challenges in translational studies? What has gone wrong thus far, and concrete examples of what needs to be done differently? How do we better understand target and drug occupancy to the translation of meaningful clinical efficacy?
•Transactional - What are emerging transaction trends in neuroscience? What sort of compelling science do we need to invest in? What type of venture and emerging partnership models are paying dividends and what could be done differently?
Session ID: 21874